Carisbamate is under clinical development by SK Life Science and currently in Phase III for Lennox-Gastaut Syndrome. According to GlobalData, Phase III drugs for Lennox-Gastaut Syndrome have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Carisbamate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Carisbamate (RWJ-333369, YKP509) is under development for the treatment of Lennox-Gastaut syndrome. The therapeutic candidate is formulated as tablet and administered orally. The drug candidate is a neuromodulator, displays high potency in a seizure. Carisbamate act as an inhibitor of voltage-gated sodium channels. It was also under development for the treatment of infantile spasms, migraine, diabetic neuropathic pain, postherpetic neuralgia, essential tremor. epilepsy, neuropathic pain and partial onset seizures and alcohol dependence.
SK Life Science overview
SK Life Science (SK Life) a subsidiary of SK Biopharmaceuticals Co Ltd is a developer of medicinal products. The company develops technologies in the areas of biology and discovery, medicinal chemistry and pharmacology. Its biology and discovery research provide lead compound discovery and optimization that indentifies and validates signal and molecular targets. SK Life develops drugs for epilepsy, sleep disorder, neuropathic pain, Alzheimer’s dementia, anxiety, depression, and schizophrenia. The company’s technical expertise includes continuous flow process and chiral chemistry. It develops drugs through partnerships with universities, government organizations, pharmaceutical and biotech companies. SK Life is headquartered in Fair Lawn, New Jersey, the US.
For a complete picture of Carisbamate’s drug-specific PTSR and LoA scores, buy the report here.